1. Home
  2. CCSI vs EDIT Comparison

CCSI vs EDIT Comparison

Compare CCSI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consensus Cloud Solutions Inc.

CCSI

Consensus Cloud Solutions Inc.

HOLD

Current Price

$34.85

Market Cap

493.6M

Sector

Technology

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.38

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCSI
EDIT
Founded
2021
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.6M
432.8M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
CCSI
EDIT
Price
$34.85
$2.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$37.50
$5.30
AVG Volume (30 Days)
152.9K
3.3M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.50
EPS
1.30
N/A
Revenue
$349,696,000.00
$31,937,000.00
Revenue This Year
$3.33
N/A
Revenue Next Year
$2.70
N/A
P/E Ratio
$26.66
N/A
Revenue Growth
N/A
132.64
52 Week Low
$19.42
$1.66
52 Week High
$37.30
$4.54

Technical Indicators

Market Signals
Indicator
CCSI
EDIT
Relative Strength Index (RSI) 64.62 38.14
Support Level $25.76 $2.24
Resistance Level $36.73 $2.76
Average True Range (ATR) 1.84 0.25
MACD 0.01 -0.06
Stochastic Oscillator 78.60 2.44

Price Performance

Historical Comparison
CCSI
EDIT

About CCSI Consensus Cloud Solutions Inc.

Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: